Toronto Dominion Bank Buys 98,843 Shares of Moderna, Inc. (NASDAQ:MRNA)

Toronto Dominion Bank grew its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 75.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 230,320 shares of the company's stock after acquiring an additional 98,843 shares during the period. Toronto Dominion Bank owned about 0.06% of Moderna worth $9,577,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in MRNA. Sender Co & Partners Inc. purchased a new stake in Moderna in the fourth quarter worth $530,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Moderna during the 4th quarter valued at $237,000. Raiffeisen Bank International AG bought a new stake in shares of Moderna during the 4th quarter valued at $159,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Moderna in the 4th quarter worth about $936,000. Finally, Quantinno Capital Management LP increased its stake in shares of Moderna by 658.0% in the 4th quarter. Quantinno Capital Management LP now owns 71,298 shares of the company's stock worth $2,965,000 after acquiring an additional 61,892 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Down 1.7%

MRNA traded down $0.46 during mid-day trading on Monday, reaching $26.26. 8,237,982 shares of the company traded hands, compared to its average volume of 8,009,025. The stock has a market capitalization of $10.16 billion, a P/E ratio of -2.83 and a beta of 1.99. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $164.73. The company's fifty day moving average price is $27.08 and its 200-day moving average price is $34.39.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.07) earnings per share. As a group, sell-side analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MRNA. William Blair restated a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and cut their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Citigroup started coverage on Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Morgan Stanley dropped their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Finally, Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.